Rational helicobacter pylori therapy: Evidence-based medicine rather than medicine-based evidence

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 2, 2014, Pages 177-186.e3

  Graham, David Y ^a   Lee, Yi Chia ^b   Wu, Ming Shiang ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Amoxicillin; Bismuth; Clarithromycin; Concomitant therapy; Evidence based; Helicobacter pylori; Metronidazole; Proton pump inhibitors; Quadruple therapy; Review; Sequential therapy; Tetracycline; Treatment; Treatment success

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH; CIPROFLOXACIN; CLARITHROMYCIN; ESOMEPRAZOLE; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; PANTOPRAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; SITOFLOXACIN; TETRACYCLINE; TINIDAZOLE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PROTOCOL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG FORMULATION; DUODENUM ULCER; DYSPEPSIA; EVIDENCE BASED MEDICINE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PATIENT COMPLIANCE; PATIENT COUNSELING; PRACTICE GUIDELINE; PREDICTION; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; CONCOMITANT THERAPY; EVIDENCE BASED; HELICOBACTER PYLORI; INTENTION TO TREAT; ITT; METRONIDAZOLE; MITT; MODIFIED INTENTION TO TREAT; PER PROTOCOL; PP; PPI; PROTON PUMP INHIBITOR; PROTON PUMP INHIBITORS; QUADRUPLE THERAPY; REVIEW; SEQUENTIAL THERAPY; TETRACYCLINE; TREATMENT; TREATMENT SUCCESS;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; BISMUTH; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; TREATMENT FAILURE;

EID: 84892481018     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.05.028     Document Type: Article

References (52)

1. Graham D.Y. Helicobacter pylori eradication therapy research: ethical issues and description of results. Clin Gastroenterol Hepatol 2010, 8:1032-1036.
2. Graham D.Y., Fischbach L.A. Empiric therapies for Helicobacter pylori infections. CMAJ 2011, 183:E506-E508.
3. Rimbara E., Fischbach L.A., Graham D.Y. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011, 8:79-88.
4. Sheiner L.B., Rubin D.B. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther 1995, 57:6-15.
5. Broutet N., Marais A., Lamouliatte H., et al. cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia. JClin Microbiol 2001, 39:1319-1322.
6. Scaccianoce G., Hassan C., Panarese A., et al. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol 2006, 20:113-117.
7. Suzuki T., Matsuo K., Ito H., et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006, 119:217-224.
8. Taneike I., Nami A., O'Connor A., et al. Analysis of drug resistance and virulence-factor genotype of Irish Helicobacter pylori strains: is there any relationship between resistance to metronidazole and cagA status?. Aliment Pharmacol Ther 2009, 30:784-790.
9. Zullo A., Perna F., Hassan C., et al. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 2007, 25:1429-1434.
10. Molina-Infante J., Romano M., Fernandez-Bermejo M., et al. Optimized non-bismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013, 145:121-128.
11. Graham D.Y., Gonzalez C., Palacios C., et al. Importance of determining the pattern of H.pylori resistance in countries with a high prevalence of gastric cancer such as Nicaragua. Helicobacter 2011, 11(Suppl 1):136.
12. Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013, 62:34-42.
13. Liou J.M., Chen C.C., Chen M.J., et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013, 381:205-213.
14. Furuta T., Graham D.Y. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am 2010, 39:465-480.
15. Essa A.S., Kramer J.R., Graham D.Y., et al. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009, 14:109-118.
16. Gisbert J.P., Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2011, 34:604-617.
17. Kongchayanun C., Vilaichone R.K., Pornthisarn B., et al. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter 2012, 17:282-285.
18. Greenberg E.R., Anderson G.L., Morgan D.R., et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pyloriinfection in seven Latin American sites: a randomised trial. Lancet 2011, 378:507-514.
19. Sardarian H., Fakheri H., Hosseini V., et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013, 18:129-134.
20. Hsu P.I., Wu D.C., Wu J.Y., et al. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (Hybrid) therapy for the final 7 days. Helicobacter 2011, 16:139-145.
21. Salazar C.O., Cardenas V.M., Reddy R.K., et al. Greater than 95% success with 14-day bismuth quadruple anti-Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter 2012, 17:382-389.
22. Liang X., Xu X., Zheng Q., et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013, 11:802-807.
23. Fischbach L., Evans E.L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007, 26:343-357.
24. Dore M.P., Farina V., Cuccu M., et al. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 2011, 16:295-300.
25. Dore M.P., Maragkoudakis E., Pironti A., et al. Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly. Helicobacter 2006, 11:52-55.
26. Graham D.Y., Belson G., Abudayyeh S., et al. Twice daily (mid-day and evening) quadruple therapy for H.pylori infection in the United States. Dig Liver Dis 2004, 36:384-387.
27. Osato M.S., Reddy R., Reddy S.G., et al. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 2001, 17:39-44.
28. Osato M.S., Graham D.Y. Etest for metronidazole susceptibility in H.pylori: use of the wrong standard may have led to the wrong conclusion. Am J Gastroenterol 2004, 99:769.
29. Malfertheiner P., Megraud F., O'Morain C.A., et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut 2012, 61:646-664.
30. Hori K., Miwa H., Matsumoto T. Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population. Helicobacter 2011, 16:234-240.
31. Graham D.Y., Rimbara E. Helicobacter pylori therapy in the west. Japanese J Helicobacter Res 2012, 13:4-9.
32. Gisbert J.P., Calvet X., O'connor A., et al. Sequential therapy for Helicobacter pylori eradication: a critical review. JClin Gastroenterol 2010, 44:313-325.
33. Graham D.Y., Shiotani A. Which therapy for Helicobacter pylori infection?. Gastroenterology 2012, 143:10-12.
34. Federico A., Nardone G., Gravina A.G., et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012, 143:55-61.
35. Graham D.Y., Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol 2012, 18:1-2.
36. Gisbert J.P., Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012, 35:209-221.
37. Borody T.J., Pang G., Wettstein A.R., et al. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006, 23:481-488.
38. Fiorini G., Vakil N., Zullo A., et al. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2013, 11:507-511.
39. Tay C.Y., Windsor H.M., Thirriot F., et al. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther 2012, 36:1076-1083.
40. Graham D.Y., Gisbert J.P. Helicobacter pylori: tailored therapy with novel sequential quadruple therapies. Nat Rev Gastroenterol Hepatol 2013, 10:6-8.
41. Graham D.Y., Calvet X. Guide regarding choice of second-line therapy toobtain a high cumulative cure rate. Helicobacter 2012, 17:243-245.
42. Attumi T.A., Graham D.Y. Follow-up testing after treatment of Helicobacter pylori infections: cautions, caveats, and recommendations. Clin Gastroenterol Hepatol 2011, 9:373-375.
43. Al-Eidan F.A., McElnay J.C., Scott M.G., et al. Management of Helicobacter pylori eradication-the influence of structured counselling and follow-up. Br J Clin Pharmacol 2002, 53:163-171.
44. Buzas G.M. Gastric tubes as vectors of Helicobacter pylori transmission. Med Hypotheses 2010, 75:47-49.
45. Laheij R.J., Rossum L.G., Jansen J.B., et al. Evaluation of treatment regimens to cure Helicobacter pylori infection-a meta-analysis. Aliment Pharmacol Ther 1999, 13:857-864.
46. Zullo A., Rinaldi V., Winn S., et al. Anew highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000, 14:715-718.
47. Jafri N.S., Hornung C.A., Howden C.W. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008, 148:923-931.
48. Gatta L., Vakil N., Leandro G., et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009, 104:3069-3079.
49. Zullo A., De F.V., Hassan C., et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007, 56:1353-1357.
50. Iovene M.R., Romano M., Pilloni A.P., et al. Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori. Chemotherapy 1999, 45:8-14.
51. Romano M., Cuomo A., Gravina A.G., et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010, 59:1465-1470.
52. Pounder R.E., Talley N.J. Letter: the ethics of using inferior regimens in H.pylori randomised trials-editors' reply. Aliment Pharmacol Ther 2012, 35:858.